GlucoTrack (GCTK) Competitors $0.25 -0.02 (-7.41%) (As of 11/21/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends GCTK vs. VERO, AEMD, CTCX, CHEK, POAI, SINT, QNRX, BBLG, NDRA, and NAOVShould you be buying GlucoTrack stock or one of its competitors? The main competitors of GlucoTrack include Venus Concept (VERO), Aethlon Medical (AEMD), Carmell (CTCX), Check-Cap (CHEK), Predictive Oncology (POAI), Sintx Technologies (SINT), Quoin Pharmaceuticals (QNRX), Bone Biologics (BBLG), ENDRA Life Sciences (NDRA), and NanoVibronix (NAOV). These companies are all part of the "medical equipment" industry. GlucoTrack vs. Venus Concept Aethlon Medical Carmell Check-Cap Predictive Oncology Sintx Technologies Quoin Pharmaceuticals Bone Biologics ENDRA Life Sciences NanoVibronix Venus Concept (NASDAQ:VERO) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings. Do institutionals & insiders have more ownership in VERO or GCTK? 87.4% of Venus Concept shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 58.0% of Venus Concept shares are owned by insiders. Comparatively, 6.3% of GlucoTrack shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, VERO or GCTK? Venus Concept has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, GlucoTrack has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500. Does the media favor VERO or GCTK? In the previous week, Venus Concept had 1 more articles in the media than GlucoTrack. MarketBeat recorded 2 mentions for Venus Concept and 1 mentions for GlucoTrack. GlucoTrack's average media sentiment score of 0.00 beat Venus Concept's score of -0.57 indicating that GlucoTrack is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Venus Concept 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative GlucoTrack 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer VERO or GCTK? Venus Concept received 34 more outperform votes than GlucoTrack when rated by MarketBeat users. CompanyUnderperformOutperformVenus ConceptOutperform Votes3465.38% Underperform Votes1834.62% GlucoTrackN/AN/A Is VERO or GCTK more profitable? GlucoTrack has a net margin of 0.00% compared to Venus Concept's net margin of -74.62%. Venus Concept's return on equity of 0.00% beat GlucoTrack's return on equity.Company Net Margins Return on Equity Return on Assets Venus Concept-74.62% N/A -47.46% GlucoTrack N/A -826.43%-707.26% Which has better valuation & earnings, VERO or GCTK? GlucoTrack has lower revenue, but higher earnings than Venus Concept. GlucoTrack is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVenus Concept$76.35M0.03-$37.25M-$8.02-0.04GlucoTrackN/AN/A-$7.10M-$2.83-0.09 SummaryVenus Concept beats GlucoTrack on 9 of the 13 factors compared between the two stocks. Ad InvestorPlaceWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.Click here now to watch the full briefing and discover the steps to take today. Get GlucoTrack News Delivered to You Automatically Sign up to receive the latest news and ratings for GCTK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GCTK vs. The Competition Export to ExcelMetricGlucoTrackSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.44M$4.42B$5.15B$8.84BDividend YieldN/A36.79%5.01%4.07%P/E Ratio-0.0925.18126.3217.62Price / SalesN/A43.631,231.8586.39Price / CashN/A52.2740.2936.27Price / Book-0.365.796.946.36Net Income-$7.10M$13.76M$119.61M$225.88M7 Day Performance-7.85%1.81%0.99%1.84%1 Month Performance-88.21%1.63%-4.26%1.67%1 Year Performance-73.34%46.11%31.27%26.69% GlucoTrack Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GCTKGlucoTrack0.0619 of 5 stars$0.25-7.4%N/A-71.0%$1.44MN/A-0.095News CoverageGap DownHigh Trading VolumeVEROVenus Concept1.2267 of 5 stars$0.29-3.3%N/A-82.6%$2.10M$76.35M-0.04410Gap DownAEMDAethlon Medical2.8509 of 5 stars$0.39flat$7.00+1,698.1%-76.8%$5.44M$570,000.00-0.1410CTCXCarmellN/A$0.25flatN/A-90.7%$5.18MN/A0.0014CHEKCheck-Cap0.5164 of 5 stars$0.82+6.5%N/A-76.2%$4.46MN/A-0.2780Upcoming EarningsGap UpPOAIPredictive Oncology2.1855 of 5 stars$0.69+6.2%$3.00+335.4%-77.1%$4.35M$1.48M-0.2330Gap UpSINTSintx Technologies0.3546 of 5 stars$4.30+15.6%N/A-94.5%$3.23M$2.63M-0.0943Gap UpQNRXQuoin Pharmaceuticals2.2347 of 5 stars$0.62-1.6%$4.00+545.2%-85.4%$3.13MN/A-0.164Negative NewsGap DownBBLGBone Biologics0.1347 of 5 stars$1.23-2.4%N/A-70.8%$3.03MN/A0.002Negative NewsNDRAENDRA Life Sciences3.6453 of 5 stars$5.16+1.8%$700,000.00+13,565,791.5%-100.0%$2.53MN/A-0.0120Gap DownNAOVNanoVibronix0.1981 of 5 stars$0.65+6.6%N/A-54.5%$2.44M$2.28M-0.5420 Related Companies and Tools Related Companies VERO Alternatives AEMD Alternatives CTCX Alternatives CHEK Alternatives POAI Alternatives SINT Alternatives QNRX Alternatives BBLG Alternatives NDRA Alternatives NAOV Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GCTK) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlucoTrack, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlucoTrack With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GCTK Stock Alerts